PhaseRx
AcquiredSeattle, US · Delaware corporation · 1 known investors
Find your way into PhaseRx
26 people in our graph share verified history with the PhaseRx team — schools, employers, funds. One of them is your warm intro.
Mike Rossunlockedknows Paul Johnson · together at Caltech (overlapped)
knows the team · via Caltech
×2knows the team · via Berlex Biosciences
×4knows the team · via Wayne State University Medical School
×4knows the team · via Jacobs School of Medicine and Biomedical Sciences at the University at Buffalo
Acquired by Roivant Sciences January 2018 · $800K ($800,000 plus assumption of certain liabilities) · source ↗
PhaseRx was a Seattle-based clinical-stage biopharmaceutical company developing mRNA-based intracellular enzyme replacement therapies for inherited liver enzyme deficiencies, initially targeting urea cycle disorders.
Founders & leadership
RW
Robert W. OverellFounder
PJ
Paul JohnsoninExecutivePaul Johnson is a biotechnology executive and scientist with over 40 years of research and development experience in drug discovery and delivery, with expertise in nucleic acid biochemistry, molecular biology, and bioinformatics. He has led programs spanning protein and oligonucleotide drug development across oncology, cardiovascular, metabolic, and infectious disease areas.
MH
Michael HoustonExecutive
AL
Andrew LeonExecutive
Board
JS
John SchmidtBoard director
BA
Brian AtwoodBoard director
SG
Steven GillisBoard director
JD
RU
Richard UlevitchBoard director
Investors · 1
Reported raises · per SEC filings
Form D private placements$7.6M disclosed across 2 of 3 rounds · 2012–2016
▶$420KofferedJun 2016 · 1 investors · BiotechnologyRule 506(b)
▶$420KofferedJun 2016 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- PAUL JOHNSONExecutive Officer, Director
- Michael HoustonExecutive Officer
- Shing-Yin (Helen) TsuiExecutive Officer
- JOHN SCHMIDTDirector
- ROBERT W. OVERELLExecutive Officer, Director, Promoter
- BRIAN ATWOODDirector
- Richard UlevitchDirector
- Michelle GriffinDirector
- STEVEN GILLISDirector
- Offering amount
- $420K
- First sale
- Jun 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$4MraisedDec 2015 · 17 investors · BiotechnologyRule 506(b)
▶$4MraisedDec 2015 · 17 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- JOHN SCHMIDTDirector
- Richard UlevitchDirector
- ROBERT W. OVERELLExecutive Officer, Director, Promoter
- PAUL JOHNSONExecutive Officer, Director
- BRIAN ATWOODDirector
- STEVEN GILLISDirector
- Michael HoustonExecutive Officer
- Offering amount
- $4M
- Amount sold
- $4M
- Sales commissions
- $280K
- Placement agents
- Palladium Capital Advisors, LLC
- First sale
- Dec 2015
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$3.6MraisedFeb 2012 · 5 investors · BiotechnologyRule 506(b)
▶$3.6MraisedFeb 2012 · 5 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Andrew LeonExecutive Officer
- Steven GillisDirector
- John D. DiekmanDirector
- John A. SchmidtDirector
- Brian G. AtwoodDirector
- Robert W. OverellExecutive Officer, Director, Promoter
- Paul H. JohnsonExecutive Officer, Director
- Offering amount
- $4.7M
- Amount sold
- $3.6M
- First sale
- Feb 2012
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- What does PhaseRx do?
- PhaseRx was a Seattle-based clinical-stage biopharmaceutical company developing mRNA-based intracellular enzyme replacement therapies for inherited liver enzyme deficiencies, initially targeting urea cycle disorders.
- Who founded PhaseRx?
- PhaseRx was founded by Robert W. Overell.
- Who are PhaseRx's investors?
- PhaseRx's investors include 5AM Ventures.
- How much funding has PhaseRx raised?
- PhaseRx has disclosed $7.6M raised across 2 of its 3 known rounds.
- Where is PhaseRx headquartered?
- PhaseRx is headquartered in Seattle, US.